A multicenter, randomized, double blind placebo-controlled trial of amoxicillin/clavulanate for the prophylaxis of fever and infection in neutropenic children with cancer
Authors:
- Luca BoniLBLuca Boni
- Mareva GiacchinoMGMareva Giacchino
- Simone CesaroSimone Cesaro
- Luigi DE SioLSLuigi DE Sio
- Alberto GaraventaAGAlberto Garaventa
- Giulio A. ZanazzoGZGiulio A. Zanazzo
- Pierfrancesco BiddauPBPierfrancesco Biddau
- Mario R. RossiMRMario R. Rossi
- Francesco SchettiniFSFrancesco Schettini
- Paolo BruzziPBPaolo Bruzzi
- Claudio ViscoliCVClaudio Viscoli
- 1 April 2003
- journal article
- clinical trial
- Published by Wolters Kluwer Health in The Pediatric Infectious Disease Journal
- Vol. 22 (4) , 359-365
Abstract
To evaluate the effectiveness of oral amoxicillin/clavulanate (25 mg/kg every 12 h) for prevention of fever and/or infection in neutropenic children with cancer. Multicenter, prospective, randomized, double blind placebo-controlled trial. In the intention-to-treat analysis, amoxicillin/clavulanate had a 12% benefit increase in terms of reduction in the incidence of febrile or infectious episodes, compared with placebo [44 of 83 (53%) vs. 55 of 84 (65%); 95% confidence interval, −28% to +3%;P = 0.101]. This benefit was also associated with a 30% increase in the probability of failure-free survival at Day 15 (P = 0.138). A logistic regression analysis showed the effect of prophylaxis to be relevant, especially in patients with leukemia or lymphoma and in those not receiving hematopoietic growth factors, with 17 and 15% absolute benefit increases (logistic P = 0.014 and 0.034, respectively). Compliance with oral drugs was good, with very few and nonsevere drug-related adverse events. In this study amoxicillin/clavulanate was associated with a detectable clinical effect in the reduction of fever and infection in neutropenic children with cancer, especially those with acute leukemia and not receiving growth factors; the study was not powered to demonstrate a statistically significant effect in the overall patient population.Keywords
This publication has 32 references indexed in Scilit:
- Rifampin Does Not Improve the Efficacy of Quinolone Antibacterial Prophylaxis in Neutropenic Cancer Patients: Results of a Randomized Clinical TrialJournal of Clinical Oncology, 2000
- Bloodstream infections in children with cancer: a multicentre surveillance study of the Italian Association of Paediatric Haematology and OncologyEuropean Journal of Cancer, 1999
- Planned progressive antimicrobial therapy in neutropenic patientsBritish Journal of Haematology, 1998
- An approach to the design and implementation of clinical trials of empirical antibiotic therapy in febrile and neutropenic cancer patientsEuropean Journal of Cancer, 1995
- Emergence of Quinolone-Resistant Escherichia coli Bacteremia in Neutropenic Patients with Cancer Who Have Received Prophylactic NorfloxacinClinical Infectious Diseases, 1995
- Reduction of fever and streptococcal bacteremia in granulocytopenic patients with cancer. A trial of oral penicillin V or placebo combined with pefloxacin. International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer1994
- Escherichia coli Resistant to Fluoroquinolones in Patients with Cancer and NeutropeniaNew England Journal of Medicine, 1994
- Evaluation of New Anti-Infective Drugs for the Treatment of Febrile Episodes in Neutropenic PatientsClinical Infectious Diseases, 1992
- Prevention of Bacterial Infection in Neutropenic Patients with Hematologic MalignanciesAnnals of Internal Medicine, 1991
- From the Immunocompromised Host Society: The Design, Analysis, and Reporting of Clinical Trials on the Empirical Antibiotic Management of the Neutropenic Patient: Report of a Consensus PanelThe Journal of Infectious Diseases, 1990